[1]王艳 马金 马世玉.焦亡/铁死亡在心肌梗死中时间和空间分布的研究进展[J].心血管病学进展,2025,(11):995.[doi:10.16806/j.cnki.issn.1004-3934.2025.11.008]
 WANG Yan,MA Jin,MA Shiyu.Temporal and Spatial Distribution of Pyroptosis and Ferroptosis in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2025,(11):995.[doi:10.16806/j.cnki.issn.1004-3934.2025.11.008]
点击复制

焦亡/铁死亡在心肌梗死中时间和空间分布的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年11期
页码:
995
栏目:
综述
出版日期:
2025-11-25

文章信息/Info

Title:
Temporal and Spatial Distribution of Pyroptosis and Ferroptosis in Myocardial Infarction
作者:
王艳 马金 马世玉
广州中医药大学第二临床医学院(广东省中医院)
Author(s):
WANG YanMA JinMA Shiyu
(The Second Clinical Medical College of Guangzhou University of Chinese Medicine,Guangdong Provincial Hospital of Traditional Chinese Medicine,State Key Laboratory of Dampness Syndrome of Traditional Chinese Medicine,Guangzhou 510000,Guangdong,China)
关键词:
心肌梗死焦亡铁死亡时空变化
Keywords:
Myocardial infarctioPyroptosisFerroptosisTemporal and spatial variation
DOI:
10.16806/j.cnki.issn.1004-3934.2025.11.008
摘要:
焦亡和铁死亡这两种程序性细胞死亡方式为理解心肌梗死的复杂病理机制提供了全新视角。这两种死亡模式不仅具有独特的分子特征,还在心肌缺血不同阶段呈现时间和空间的动态分布,成为干预心肌损伤的关键靶标,这对于该疾病的防治具有重要意义。现对心肌梗死后焦亡和铁死亡的时间和空间分布进行综述,以期为该病的防治提供新的思路。
Abstract:
Pyroptosis and ferroptosis,two distinct forms of programmed cell death, provide novel mechanistic insights into the complex pathophysiology of myocardial infarction. Characterized by unique molecular signatures and dynamic temporal and spatial distribution during different phases of myocardial ischemia ,which become the key targets for intervention of myocardial injury and are of great significance for the prevention and treatment of this disease. The review summarizes the temporal and spatial characteristics of pyroptosis and ferroptosis following myocardial infarction,aiming to provide new perspectives for therapeutic strategies.

参考文献/References:

[1].Piamsiri C,Maneechote C,Jinawong K,et al. GSDMD-mediated pyroptosis dominantly promotes left ventricular remodeling and dysfunction in post-myocardial infarction:a comparison across modes of programmed cell death and mitochondrial involvement[J]. J Transl Med,2023,21(1):16.
[2].Yanpiset P,Maneechote C,Sriwichaiin S,et al. Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury:cumulative evidence for future cardioprotective strategies[J]. Acta Pharm Sin B,2023,13(1):29-53.
[3].Zheng Y,Xu X,Chi F,et al. Pyroptosis:a newly discovered therapeutic target for ischemia-reperfusion injury[J]. Biomolecules,2022,12(11):1625.
[4].Lu LQ,Tian J,Luo XJ,et al. Targeting the pathways of regulated necrosis:a potential strategy for alleviation of cardio-cerebrovascular injury[J]. Cell Mol Life Sci,2021,78(1):63-78.
[5].Han X,Zhang J,Liu J,et al. Targeting ferroptosis:a novel insight against myocardial infarction and ischemia-reperfusion injuries[J]. Apoptosis,2023,28(1-2):108-123.
[6].Tang LJ,Luo XJ,Tu H,et al. Ferroptosis occurs in phase of reperfusion but not ischemia in rat heart following ischemia or ischemia/reperfusion[J]. Naunyn Schmiedebergs Arch Pharmacol,2021,394(2):401-410.
[7].Pan Y,Wang X,Liu X,et al. Targeting ferroptosis as a promising therapeutic strategy for ischemia-reperfusion injury[J]. Antioxidants (Basel),2022,11(11):2196.
[8].Wu J,Cai H,Lei Z,et al. Expression pattern and diagnostic value of ferroptosis-related genes in acute myocardial infarction[J]. Front Cardiovasc Med,2022,9:993592.
[9].Ye X,Hang Y,Lu Y,et al. CircRNA circ-NNT mediates myocardial ischemia/reperfusion injury through activating pyroptosis by sponging miR-33a-5p and regulating USP46 expression[J]. Cell Death Discov,2021,7(1):370.
[10].Sun W,Lu H,Dong S,et al. Beclin1 controls caspase-4 inflammsome activation and pyroptosis in mouse myocardial reperfusion-induced microvascular injury[J]. Cell Commun Signal,2021,19(1):107.
[11].Li H,Yang DH,Zhang Y,et al. Geniposide suppresses NLRP3 inflammasome-mediated pyroptosis via the AMPK signaling pathway to mitigate myocardial ischemia/reperfusion injury[J]. Chin Med,2022,17(1):73.
[12].Liu W,Shen J,Li Y,et al. Pyroptosis inhibition improves the symptom of acute myocardial infarction[J]. Cell Death Dis,2021,12(10):852.
[13].Wang X,Li X,Liu S,et al. PCSK9 regulates pyroptosis via mtDNA damage in chronic myocardial ischemia[J]. Basic Res Cardiol,2020,115(6):66.
[14].Li M,Wang Y,Qi Z,et al. QishenYiqi dripping pill protects against myocardial ischemia/reperfusion injury via suppressing excessive autophagy and NLRP3 inflammasome based on network pharmacology and experimental pharmacology[J]. Front Pharmacol,2022,13:981206.
[15].Chai R,Ye Z,Xue W,et al. Tanshinone ⅡA inhibits cardiomyocyte pyroptosis through TLR4/NF-κB p65 pathway after acute myocardial infarction[J]. Front Cell Dev Biol,2023,11:1252942.
[16].Jiang Y,Qiao Y,He D,et al. Adaptor protein HIP-55-mediated signalosome protects against ferroptosis in myocardial infarction[J]. Cell Death Differ,2023,30(3):825-838.
[17].Miyamoto HD,Ikeda M,Ide T,et al. Iron overload via heme degradation in the endoplasmic reticulum triggers ferroptosis in myocardial ischemia-reperfusion injury[J]. JACC Basic Transl Sci,2022,7(8):800-819.
[18].Sun S,Wu Y,Maimaitijiang A,et al. Ferroptotic cardiomyocyte-derived exosomes promote cardiac macrophage M1 polarization during myocardial infarction[J]. PeerJ,2022,10:e13717.
[19].Han X,Zhao ZA,Yan S,et al. CXADR-like membrane protein protects against heart injury by preventing excessive pyroptosis after myocardial infarction[J]. J Cell Mol Med,2020,24(23):13775-13788.
[20].Zhang KZ,Shen XY,Wang M,et al. Retinol-binding protein 4 promotes cardiac injury after myocardial infarction via inducing cardiomyocyte pyroptosis through an interaction with NLRP3[J]. J Am Heart Assoc,2021,10(22):e022011.
[21].Wang K,Sun Y,Zhu K,et al. Anti-pyroptosis biomimetic nanoplatform loading puerarin for myocardial infarction repair:from drug discovery to drug delivery[J]. Biomaterials,2025,314:122890.
[22].Ye X,Zhang P,Zhang Y,et al. GSDMD contributes to myocardial reperfusion injury by regulating pyroptosis[J]. Front Immunol,2022,13:893914.
[23].Zhang M,Lei YS,Meng XW,et al. Iguratimod alleviates myocardial ischemia/reperfusion injury through inhibiting inflammatory response induced by cardiac fibroblast pyroptosis via COX2/NLRP3 signaling pathway[J]. Front Cell Dev Biol,2021,9:746317.
[24].Lu P,Qi Y,Li X,et al. PEDF and 34-mer peptide inhibit cardiac microvascular endothelial cell ferroptosis via Nrf2/HO-1 signalling in myocardial ischemia-reperfusion injury[J]. J Cell Mol Med,2024,28(14):e18558.
[25].Wang Z,Yao M,Jiang L,et al. Dexmedetomidine attenuates myocardial ischemia/reperfusion-induced ferroptosis via AMPK/GSK-3β/Nrf2 axis[J]. Biomed Pharmacother,2022,154:113572.
[26].Chen W,Zhang Y,Wang Z,et al. Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition[J]. Front Pharmacol,2023,14:1078205.
[27].Xu S,Wu B,Zhong B,et al. Naringenin alleviates myocardial ischemia/reperfusion injury by regulating the nuclear factor-erythroid factor 2-related factor 2 (Nrf2) /System xc-/ glutathione peroxidase 4 (GPX4) axis to inhibit ferroptosis[J]. Bioengineered,2021,12(2):10924-10934.
[28].Yuan Y,Huang H,Hu T,et al. Curcumin pretreatment attenuates myocardial ischemia/reperfusion injury by inhibiting ferroptosis,autophagy and apoptosis via HES1[J]. Int J Mol Med,2024,54(6):110.
[29].Mohr ME,Li S,Trouten AM,et al. Cardiomyocyte-fibroblast interaction regulates ferroptosis and fibrosis after myocardial injury[J]. bioRxiv,2023 Feb 8:2023.02.07.527364. DOI:10.1101/2023.02.07.527364.
[30].Zhang AY,Su JB,Sun HT,et al. Stachyose ameliorates myocardial ischemia-reperfusion injury by inhibiting cardiomyocyte ferroptosis and macrophage pyroptosis[J]. Int Immunopharmacol,2024,143(Pt 1):113334.
[31].Hu T,Zou HX,Le SY,et al. Tanshinone IIA confers protection against myocardial ischemia/reperfusion injury by inhibiting ferroptosis and apoptosis via VDAC1[J]. Int J Mol Med,2023,52(5):109.
[32].Chen X,Lin S,Dai S,et al. Trimetazidine affects pyroptosis by targeting GSDMD in myocardial ischemia/reperfusion injury[J]. Inflamm Res,2022,71(2):227-241.
[33].Tan M,Yin Y,Chen W,et al. Trimetazidine attenuates Ischemia/Reperfusion-Induced myocardial ferroptosis by modulating the Sirt3/Nrf2-GSH system and reducing Oxidative/Nitrative stress[J]. Biochem Pharmacol,2024,229:116479.
[34].Wang L,Liu J,Wang Z,et al. Dexmedetomidine abates myocardial ischemia reperfusion injury through inhibition of pyroptosis via regulation of miR-665/MEF2D/Nrf2 axis[J]. Biomed Pharmacother,2023,165:115255.
[35].Fu Y,Wang Q,Wang D,et al. Dexmedetomidine inhibits ferroptosis to alleviate hypoxia/reoxygenation-induced cardiomyocyte injury by regulating the HDAC2/FPN pathway[J]. Cardiovasc Drugs Ther,2025 Jan 2. DOI:10.1007/s10557-024-07664-z.

相似文献/References:

[1]王铁华,郑景辉,莫云秋.蛋白质组学在心肌梗死中的研究进展[J].心血管病学进展,2015,(5):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
 WANG Tiehua,ZHENG Jinghui,MO Yunqiu.Research Progress of Proteomics in Myocardial Infarction[J].Advances in Cardiovascular Diseases,2015,(11):616.[doi:10.3969/j.issn.1004-3934.2015.05.024]
[2]孙洋.基质金属蛋白酶与心肌梗死后心脏重构[J].心血管病学进展,2019,(8):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
 SUN Yang.Matrix Metalloproteinases in Cardiac Remodeling after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(11):1094.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.006]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
 CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(11):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]常文婧 王丽娜.Hippo通路在心脏发育、再生和疾病中的作用[J].心血管病学进展,2019,(8):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
 CHANG Wenjin,WANG Lina.Role of Hippo Pathway in Heart Development,Regeneration and Disease[J].Advances in Cardiovascular Diseases,2019,(11):1115.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.011]
[5]王宇 周思维 张莎 吴弘.植入型心律转复除颤器在心肌梗死后心脏性猝死中的研究进展[J].心血管病学进展,2020,(1):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
 WANG Yu,ZHOU Siwei,ZHANG Sha,et al.Implantable Cardioverter Defibrillator in Sudden Cardiac Death after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(11):4.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.002]
[6]邹先明 赵然尊.长链非编码RNA ANRIL与心血管疾病的研究进展[J].心血管病学进展,2020,(2):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
 ZOU Xianming,ZHAO Ranzun.Long Non-Coding RNA ANRIL and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(11):167.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.017]
[7]王茜 李晶洁.细胞学机制在调控心肌梗死后炎症反应中的研究进展[J].心血管病学进展,2020,(2):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
 WANG QianLI Jingjie.Cytological Mechanisms in Regulation of The Post-infarction Inflammatory Response[J].Advances in Cardiovascular Diseases,2020,(11):190.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.023]
[8]黄柳,张瑞宁,田小超,等.内皮祖细胞与冠心病患者CD14CD16+单核细胞共培养后移植心肌梗死大鼠对血管密度及心肌梗死面积的影响[J].心血管病学进展,2020,(2):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
 HUANG Liu,ZHANG Ruining,TIAN Xiaochao,et al.Effects of Co-cultured Endothelial Progenitor Cells and CD14++CD16+ Monocytes from Coronary Heart Disease Patients on Vascular Density and Myocardial Infarction Size in Transplanting Myocardial Infarction Rats[J].Advances in Cardiovascular Diseases,2020,(11):203.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.027]
[9]刘玉婷,贾锋鹏.骨膜蛋白与心血管疾病的研究进展[J].心血管病学进展,2020,(3):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
 LIU Yuting,JIA Fengpeng.Roles of Periostin in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(11):239.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.006]
[10]谢建华,赵鸿泽,刘剑雄.MicroRNA在心肌梗死后左室重塑和心力衰竭发展中的研究现状[J].心血管病学进展,2020,(3):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
 XIE Jianhua,ZHAO Hongze,LIU Jianxiong.MicroRNA in Development of Left Ventricular Remodeling and Heart Failure after Myocardial Infarction[J].Advances in Cardiovascular Diseases,2020,(11):259.[doi:10.16806 /j.cnki.issn.1004-3934.2020.03.011]
[11]刘文秀 郭雨桐 孙雪 宋琳琳 刘越 丁雪.Calhex231通过焦亡改善大鼠心肌梗死面积大小及心脏纤维化[J].心血管病学进展,2024,(4):379.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.000]
 LIU Wenxiu,GUO Yutong,SUN Xue,et al.Calhex231 Attenuates Rat Myocardial Infarct Size and Fibrosis by Suppressing Pyroptosis[J].Advances in Cardiovascular Diseases,2024,(11):379.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.000]

更新日期/Last Update: 2026-03-06